Detalhe da pesquisa
1.
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
Immunity
; 53(6): 1315-1330.e9, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33275896
2.
Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.
J Transl Med
; 22(1): 349, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38610029
3.
A tetravalent nanoparticle vaccine elicits a balanced and potent immune response against dengue viruses without inducing antibody-dependent enhancement.
Front Immunol
; 14: 1193175, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37275868
4.
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2.
Cell Rep
; 38(3): 110256, 2022 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34990583
5.
Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques.
Cell Mol Immunol
; 18(4): 1058-1060, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33580167
6.
Symptom experienced three years after liver transplantation under immunosuppression in adults.
PLoS One
; 8(11): e80584, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24260427